- Home
- AVDX vs AZTA Comparison
AVDX vs AZTA Comparison
Compare AVDX & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- AZTA
- Stock Information
- Founded
- AVDX 2000
- AZTA 1978
- Country
- AVDX United States
- AZTA United States
- Employees
- AVDX N/A
- AZTA N/A
- Industry
- AVDX EDP Services
- AZTA Industrial Machinery/Components
- Sector
- AVDX Technology
- AZTA Technology
- Exchange
- AVDX Nasdaq
- AZTA Nasdaq
- Market Cap
- AVDX 2.0B
- AZTA 1.8B
- IPO Year
- AVDX 2021
- AZTA 1995
- Fundamental
- Price
- AVDX $9.80
- AZTA $30.77
- Analyst Decision
- AVDX Hold
- AZTA Buy
- Analyst Count
- AVDX 15
- AZTA 3
- Target Price
- AVDX $10.04
- AZTA $50.67
- AVG Volume (30 Days)
- AVDX 3.4M
- AZTA 1.0M
- Earning Date
- AVDX 07-30-2025
- AZTA 08-05-2025
- Dividend Yield
- AVDX N/A
- AZTA N/A
- EPS Growth
- AVDX N/A
- AZTA N/A
- EPS
- AVDX 0.01
- AZTA N/A
- Revenue
- AVDX $441,284,000.00
- AZTA $669,171,000.00
- Revenue This Year
- AVDX $5.56
- AZTA N/A
- Revenue Next Year
- AVDX $10.01
- AZTA $4.89
- P/E Ratio
- AVDX $1,097.76
- AZTA N/A
- Revenue Growth
- AVDX 10.46
- AZTA 8.56
- 52 Week Low
- AVDX $6.61
- AZTA $23.91
- 52 Week High
- AVDX $12.93
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- AVDX 67.92
- AZTA 59.63
- Support Level
- AVDX $9.75
- AZTA $28.46
- Resistance Level
- AVDX $9.81
- AZTA $30.86
- Average True Range (ATR)
- AVDX 0.03
- AZTA 1.19
- MACD
- AVDX -0.04
- AZTA 0.08
- Stochastic Oscillator
- AVDX 69.23
- AZTA 79.30
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.